Cargando…

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

BACKGROUND AND OBJECTIVES: In clinical trials, the safety of drugs is summarized by the incidence of adverse events, while post-marketing reporting systems use disproportionate reporting of adverse drug reactions. Here, we propose a method to evaluate the novelty of a safety profile of a drug in a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Hopkins, Seth C., Ogirala, Ajay, Worden, MaryAlice, Koblan, Kenneth S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626367/
https://www.ncbi.nlm.nih.gov/pubmed/34751928
http://dx.doi.org/10.1007/s40261-021-01094-7